Search

Your search keyword '"B. Gallwitz"' showing total 10 results
Start Over Author "B. Gallwitz" Journal mmw fortschritte der medizin
10 results on '"B. Gallwitz"'

1. [Insulin degludec--a new basal insulin for the treatment of type 1 and type 2 diabetes]

Author

B, Gallwitz and T, Haak

Subjects
Blood Glucose, Insulin, Long-Acting, Diabetes Mellitus, Type 1, Clinical Trials, Phase III as Topic, Diabetes Mellitus, Type 2, Delayed-Action Preparations, Injections, Subcutaneous, Biological Availability, Humans, Drug Administration Schedule, Half-Life
Abstract

After subcutaneous injection, IDeg self-associates to form multihexamer chains that slowly dissociate into monomers. This results in a duration of action of more than 42 hours as well as a smooth level action profile with low intra-individual variability. Pharmacokinetic studies foun IDeg to have a half-life of approximately 25 hours which is considerably longer than that from other current insulin formulations. Based on these properties, IDeg demonstrated low risk for nocturnal hypoglycaemic events in the clinical study program. Concurrently, phase 3 studies have provided evidence for a non-inferior glucose lowering effect when compared to other currently available basal insulin formulations. Moreover, the long duration of action suggests a flexible handling which could be better adapted to patients' needs in daily routine. This article gives an overview of the mechanism of action of IDeg and the latest results from phase 2 and phase 3 studies.

Published
2014

6. [Assessment of novel antidiabetic drugs in Germany. Do innovations still have a chance?].

Author

Gallwitz B

Subjects
Administration, Oral, Age Factors, Consensus, Costs and Cost Analysis economics, Costs and Cost Analysis legislation & jurisprudence, Diabetes Complications economics, Diabetes Complications prevention & control, Diabetes Mellitus, Type 2 diagnosis, Dipeptidyl-Peptidase IV Inhibitors adverse effects, Dipeptidyl-Peptidase IV Inhibitors economics, Dipeptidyl-Peptidase IV Inhibitors therapeutic use, Drug Costs legislation & jurisprudence, Drug Industry economics, Drugs, Investigational adverse effects, Drugs, Investigational economics, Germany, Glucagon-Like Peptide-1 Receptor, Humans, Hypoglycemic Agents adverse effects, Hypoglycemic Agents economics, Injections, Subcutaneous, National Health Programs economics, Receptors, Glucagon antagonists & inhibitors, Diabetes Mellitus, Type 2 drug therapy, Drug Approval, Drugs, Investigational therapeutic use, Hypoglycemic Agents therapeutic use
Published
2014

7. [Insulin degludec--a new basal insulin for the treatment of type 1 and type 2 diabetes].

Author

Gallwitz B and Haak T

Subjects
Biological Availability, Blood Glucose metabolism, Clinical Trials, Phase III as Topic, Delayed-Action Preparations, Diabetes Mellitus, Type 1 blood, Diabetes Mellitus, Type 2 blood, Drug Administration Schedule, Half-Life, Humans, Injections, Subcutaneous, Insulin, Long-Acting administration & dosage, Insulin, Long-Acting pharmacokinetics, Diabetes Mellitus, Type 1 drug therapy, Diabetes Mellitus, Type 2 drug therapy, Insulin, Long-Acting therapeutic use
Abstract

After subcutaneous injection, IDeg self-associates to form multihexamer chains that slowly dissociate into monomers. This results in a duration of action of more than 42 hours as well as a smooth level action profile with low intra-individual variability. Pharmacokinetic studies foun IDeg to have a half-life of approximately 25 hours which is considerably longer than that from other current insulin formulations. Based on these properties, IDeg demonstrated low risk for nocturnal hypoglycaemic events in the clinical study program. Concurrently, phase 3 studies have provided evidence for a non-inferior glucose lowering effect when compared to other currently available basal insulin formulations. Moreover, the long duration of action suggests a flexible handling which could be better adapted to patients' needs in daily routine. This article gives an overview of the mechanism of action of IDeg and the latest results from phase 2 and phase 3 studies.

Published
2013
Full Text
View/download PDF

9. [Diabetes therapy--novel drugs to come (DPP-4 inhibitors, GLP-1 agonists, SGLT-2 inhibitors)].

Author

Gallwitz B

Subjects
Clinical Trials as Topic, Dipeptidyl Peptidase 4, Drug Therapy, Combination, Germany, Humans, Sodium-Glucose Transporter 2, Diabetes Mellitus, Type 2 drug therapy, Dipeptidyl-Peptidase IV Inhibitors, Drugs, Investigational therapeutic use, Glucagon-Like Peptide 1 agonists, Hypoglycemic Agents therapeutic use, Sodium-Glucose Transporter 2 Inhibitors
Published
2010
Full Text
View/download PDF

10. [A new long-acting insulin analog. "Fewer hypoglycemias observed"].

Author

Gallwitz B

Subjects
Blood Glucose analysis, Clinical Trials as Topic, Diabetes Mellitus, Type 1 blood, Diabetes Mellitus, Type 2 blood, Humans, Injections, Subcutaneous, Insulin administration & dosage, Insulin agonists, Insulin Detemir, Insulin Glargine, Insulin, Long-Acting, Time Factors, Diabetes Mellitus, Type 1 drug therapy, Diabetes Mellitus, Type 2 drug therapy, Insulin analogs & derivatives, Insulin therapeutic use
Published
2004

Catalog

Books, media, physical & digital resources
See catalog results